Session Details

P021 Clinical Dermatology in Aging People

Sat, Jul 12, 3:30 PM - 5:30 PM
Grand Hall J
2 CME Available 2 Hour Parallel
View Map

DESCRIPTION

The number and proportion of people aged 60 years and older in the population is increasing. In 2019, the number of people aged 60 years and older was 1 billion. According the WHO this number will increase to 1.4 billion by 2030. Undoubtedly, dermatologists will be confronted with many more geriatric patients with diseases that are augmented by aging and even the presentation of new entities. In this session we will present some aspects of psoriasis and bullous pemphigoid in elderly patients, but also STIs, how psychodermatology can help in particular situations, and finally specificities of systemic therapy in elderly.

LEARNING OBJECTIVES

1.

Diagnose different dermatological conditions in mature patients.

2.

Evaluate all potential threats when choosing most appropriate therapy with special emphasis on the age of the patient.

3.

Select the best treatment for each condition.

SCHEDULE

8:30 PM

Introduction

Branka Marinovic, MD, PhD, IFAAD

8:35 PM

Special Factors to Consider in Elderly patients with Psoriasis

Mark Lebwohl, MD, FAAD

8:55 PM

Bullous pemphigoid - What is new in 2025?

Branka Marinovic, MD, PhD, IFAAD

9:15 PM

Q & A

Branka Marinovic, MD, PhD, IFAAD, Mark Lebwohl, MD, FAAD

9:20 PM

Old and Bold: Managing STD in 65+ Club

George S. Tiplica, MD, PhD, IFAAD

9:40 PM

Psychodermatology, age sometimes matters

Menno Alexander De Rie, MD, PhD, IFAAD

10:00 PM

Mastering systemic therapy in elderly patients

Carmen M Salavastru, MD, PhD, IFAAD

10:20 PM

Q & A

Menno Alexander De Rie, MD, PhD, IFAAD, Carmen M Salavastru, MD, PhD, IFAAD, George S. Tiplica, MD, PhD, IFAAD

SPEAKERS

Menno Alexander De Rie, MD, PhD, IFAAD

Menno Alexander De Rie, MD, PhD, IFAAD

European Academy of Dermatolgoy & Venereology

Mark Lebwohl, MD, FAAD

Mark Lebwohl, MD, FAAD

Icahn School of Medicine at Mount Sinai

Branka Marinovic, MD, PhD, IFAAD

Branka Marinovic, MD, PhD, IFAAD

Carmen M Salavastru, MD, PhD, IFAAD

Carmen M Salavastru, MD, PhD, IFAAD

George S. Tiplica, MD, PhD, IFAAD

George S. Tiplica, MD, PhD, IFAAD

HANDOUTS

Login to view handouts

SPEAKER DISCLOSURES

Menno Alexander De Rie, MD, PhD, IFAAD

No financial relationships exist with ineligible companies.

Mark Lebwohl, MD, FAAD

AbbVie – Investigator(Grants/Research Funding); Aikium – Consultant (1099 relationship)(Honoraria); Almirall – Consultant(Honoraria); AltruBio Inc. – Consultant(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Honoraria); Atomwise – Consultant(Honoraria); Avotres, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Consultant(Honoraria); Celltrion – Consultant(Honoraria); Clexio Biosciences, Ltd – Investigator(Grants/Research Funding); CoreEvitas, LLC – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); Dermsquared – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Evommune, Inc. – Consultant(Honoraria); Facilitation of International Dermatology Education – Consultant(Honoraria); Forte Biosciences – Consultant(Honoraria); Galderma – Consultant(Honoraria); Genentech, Inc. – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Inozyme Pharma – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Leo Pharma A/S – Consultant(Honoraria); Mayne Pharma Group – Consultant (1099 relationship)(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Honoraria); Mindera – Consultant(Honoraria); Mirum Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); New York College of Podiatric Medicine – Speaker/Faculty Education(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Seanergy Maritime Holdings Corp. – Consultant(Honoraria); Strata Skin Sciences – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Trevi Therapeutics – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Consultant(Honoraria);

Branka Marinovic, MD, PhD, IFAAD

No financial relationships exist with ineligible companies.

Carmen M Salavastru, MD, PhD, IFAAD

Axel Springer AG – Other(Patent royalties or other compensation for Intellectual Property Rights);

George S. Tiplica, MD, PhD, IFAAD

Abbott Laboratories – Speaker(Honoraria); Antibiotice SA – Speaker(Honoraria); Bristol Myers Squibb – Speaker(Honoraria); Organon Biosciences SRL – Speaker(Honoraria);